Press Releases

Results of EndoBarrier Therapy Studies Presented at Digestive Disease Week Meeting

Results of EndoBarrier Therapy Studies Presented at Digestive Disease Week Meeting EndoBarrier mechanism-of-action study shows ~18 kg mean weight loss and negative correlation between fat absorption and weight loss1 EndoBarrier treatment shows reduction in hepatic fat of 81% and 6x liraglutide...

read more

EndoBarrier Therapy Data to be Presented at American Diabetes Association Annual Meeting

EndoBarrier Therapy Data to be Presented at American Diabetes Association Annual Meeting LEXINGTON, Massachusetts and SYDNEY, Australia – 9 June 2016 – GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative endoscopically delivered treatment for type 2 diabetes and...

read more

GI Dynamics Appoints Chief Compliance Officer

GI Dynamics Appoints Chief Compliance Officer LEXINGTON, Mass & SYDNEY, Australia – 10 May 2016 AEST – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Brian Callahan...

read more

GI Dynamics Releases Safety and Efficacy Data for EndoBarrier Therapy

GI Dynamics Releases Safety and Efficacy Data for EndoBarrier Therapy LEXINGTON, Massachusetts and SYDNEY, Australia – 9 May 2016 AEST – GI Dynamics, Inc. (ASX:GID), a medical device company that develops innovative endoscopically delivered treatments for type 2 diabetes and obesity, announced new...

read more

GI Dynamics Appoints Chief Financial Officer

GI Dynamics Appoints Chief Financial Officer LEXINGTON, Massachusetts & SYDNEY, Australia – 5 May 2016 AEST – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Jim...

read more

Daniel J. Moore Elected Chairman of the Board

Daniel J. Moore Elected Chairman of the Board LEXINGTON, Massachusetts & SYDNEY, Australia – 3 May 2016 AEST – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides innovative treatments for type 2 diabetes and obesity, is pleased to announce that the board of...

read more

Appendix 4C Quarterly Report Quarter Ended 31 March 2016

Appendix 4C Quarterly Report Quarter Ended 31 March 2016 LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 29 April 2016 – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, releases its Appendix 4C...

read more

GI Dynamics Announces the Appointment of Medical Device Industry Veteran Scott Schorer as President & Chief Executive Officer

GI Dynamics Announces the Appointment of Medical Device Industry Veteran Scott Schorer as President & Chief Executive Officer LEXINGTON, Massachusetts & SYDNEY, Australia –23 March 2016 AEDT –The Board of Directors of GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company...

read more

GI Dynamics Announces Top-Line Results from U.S. Pivotal Clinical Trial of EndoBarrier® Therapy (the ENDO Trial)

GI Dynamics Announces Top-Line Results from U.S. Pivotal Clinical Trial of EndoBarrier® Therapy (the ENDO Trial) GI Dynamics to Hold Conference Call and Webcast at 8:30 a.m. AEDT on 16 March 2016 (5:30 p.m. EDT on 15 March 2016) LEXINGTON, Massachusetts & SYDNEY, Australia – 15 March 2016 AEDT...

read more

GI Dynamics, Inc. Provides 2017 Business Outlook and 2016 Review

BOSTON and SYDNEY — 11 January 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe for patients with type 2 diabetes and obesity, today released a 2017 business outlook and recap of 2016 accomplishments. 2017 marks the first full calendar...

read more
Page 3 of 1712345...10...Last »